Transcript 2014 Industry Snapshot Massachusetts Biopharma Industry Employment 57,642 Employment in the industry has grown 9-10 x faster than state and national growth rates for all employment.* 54,280 54,829 55,342 56,097 56,462 51,518 46,117 43,904 41,128 41 % *4.8% MA.

2014 Industry Snapshot
Massachusetts Biopharma Industry
Employment
57,642
Employment in
the industry has
grown 9-10 x
faster than state
and national
growth rates for all
employment.*
54,280
54,829 55,342
56,097
56,462
51,518
46,117
43,904
41,128
41 %
*4.8% MA 10-year
employment growth, all
industries
4.1% US 10-year
employment growth, all
industries
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
Source: U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW); MassBio
Economic Impact - 2013
57,642 employees
$125,056 average salary
$7,208,460,412 total MA-based payroll
Source: U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW)
10 - Year Employment Performance:
MANUFACTURING
The U.S. lost
10,091 biopharma
manufacturing
jobs since 2004, a
3.6% decrease.
Massachusetts
grew by 24.2% in
biopharma
manufacturing in
the same time
period.
California
New Jersey
North Carolina
New York
Illinois
Pennsylvania
Indiana
Puerto Rico
Texas
Massachusetts
Michigan
Maryland
Connecticut
Ohio
Missouri
2004
2013
40,501
45,141
39,680
26,720
20,646
21,629
21,640
19,918
20,597
17,931
23,308
17,926
20,057
17,820
28,062
13,971
9,241
10,145
6,977
9,322
10,057
8,181
5,241
6,901
9,758
6,158
4,746
5,736
5,239
5,474
=/- %
10.7%
-38.1%
4.9%
-8.4%
-14.7%
-24.8%
-12.7%
-69.8%
9.1%
24.2%
-24.1%
26.0%
-48.6%
19.1%
4.9%
Top 5 in job growth
CA
MA
MD
OH
NC
4,640
2,345
1,660
990
983
Top 5 in
Percentage Growth
MD
MA
OH
CA
TX
26.0%
24.2%
19.1%
10.7%
9.1%
Source: U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW)
7 - Year Employment Performance:
Biotechnology Research & Development
Massachusetts
has more
employment
classified as
Biotechnology
Research and
Development
than any other
state.*
*NAICS 541711:
Research and
development in
biotechnology
2007
2013
=/-%
Massachusetts
24,656
28,042
13.7%
California
19,134
24,196
26.5%
Pennsylvania
16,902
10,854
-35.8%
Maryland
10,154
8,014
-21.1%
New Jersey
8,567
9,362
9.3%
North Carolina
7,042
7,080
0.5%
Michigan
4,670
2,678
-42.7%
Missouri
4,262
3,437
-19.4%
Texas
4,229
4,861
14.9%
Ohio
2,696
3,100
15.0%
New York
2,679
4,119
53.8%
Washington
2,499
3,602
44.1%
Connecticut
2,452
2,963
20.8%
Illinois
2,403
2,963
23.3%
Indiana
1,277
1,657
29.8%
Florida
737
Top 5 in job growth
CA
MA
FL
NY
WA
5,062
3,386
1,633
1,440
1,103
Top 5 in
Percentage Growth
FL
NY
WA
IN
CA
221.6%
53.8%
44.1%
29.8%
26.5%
2,370 221.6%
Source: U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW)
Apples to Apples
As explained in the appendix, MassBio uses 8 industry classifications in determining
overall employment in the biopharma industry. This reflects a conservative approach, as
other reports include other industry classifications. In estimating employment
attributable to the biopharma industry, MassBio uses only a percentage of employment
reported for several industry classifications (1.9% of university employment, for
example). Our determination of what percentage to utilize in our estimate is determined
by the unique composition of these industries in Massachusetts. As the profile of each
such industry segment varies by state, it not appropriate to compare these particular
industry segments using the percentages that we have developed specifically for
Massachusetts.
Fortunately, two NAICS classifications, Pharmaceutical Manufacturing (NAICS 3254)
and Research and Development in Biotechnology (NAICS 541711) , are considered
fully part of the biopharma industry and would be so considered in any state.
Additionally, these two industry segments are core segments of the industry. These two
industries, therefore, are particularly appropriate for “apples to apples” comparisons to
determine industry performance among the biopharma states.
Therefore, we have considered ONLY two NAICS codes for the following state-to-state
employment performance comparison: NAICS 3254, Pharmaceutical Manufacturing,
and NAICS 541711, Research and Development in Biotechnology.
Apples to Apples: Core Biopharma
employment performance since 2007
California
Massachusetts
New Jersey
Pennsylvania
North Carolina
New York
Illinois
Indiana
Texas
Maryland
Puerto Rico
Michigan
Missouri
Ohio
Connecticut
2007
63,105
33,795
50,823
39,009
26,266
24,420
21,057
20,802
14,133
16,374
24,580
12,925
9,466
7,770
11,277
2013
69,337
37,364
36,082
28,780
28,709
24,037
20,894
19,477
15,006
14,915
14,004
10,859
8,911
8,836
7,941
=/-#
6,232
3,569
-14,741
-10,229
2,443
-383
-163
-1,325
873
-1,459
-10,576
-2,066
-555
1,066
-3,336
+/- %
Top 5 in job growth
9.9%
10.6%
CA
6,232
-29.0%
MA
3,569
-26.2%
NC
2,443
9.3%
OH
1,066
-1.6%
TX
873
-0.8%
Top 5 in
-6.4%
6.2% Percentage Growth
-8.9%
OH
13.7%
-43.0%
MA
10.6%
-16.0%
CA
9.9%
-5.9%
NC
9.3%
13.7%
TX
6.2%
-29.6%
Source: U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW)
Biopharma Manufacturing Employment, 2013
•
Massachusetts is also a leading state in biopharma manufacturing, with
1 out of 5 jobs in the industry involved in manufacturing.
•
With over 600,000 liters of mammalian cell culture manufacturing
capacity in the region, Massachusetts is the leader globally in this type of
biologics manufacturing expertise.
Medical Device Employment in MA
Only California
and Minnesota
employ more in
the medical
device industry.
22,501
22,390
21,765
22,946
22,155
21,978
23,151
22,127
22,124
21,304
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
Source: U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW)
R&D in Biotech: Industry Concentration
9.00
What is a Location
Quotient?
8.00
7.00
6.00
Massachusetts
holds a dominant
position in terms of
industry
concentration in
“Biotechnology
Research and
Development” –
almost twice the
concentration of
jobs as the next
closest state.
5.00
2009
2013
4.00
3.00
2.00
1.00
0.00
CA
MD
MA
MO
NJ
NC
PA
Location Quotients are
used by economists to
determine the strength of an
industry in a geographic
region. They measure the
concentration and strength
of an industry in a region
versus the nation as a
whole. Location Quotients
of more that 1.0 mean that
the industry enjoys a
greater concentration in a
region versus the nation as
a whole.
WA
Source: U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW)
2013 National Institutes of Health (NIH)
Funding - by State Total (millions) and Per Capita
Massachusetts
trailed only
California in total
dollars in 2012.
$350
CA
MA
NY
MD
PA
TX
NC
WA
IL
US
HOWEVER,
NIH funding was
reduced by
12.2% nationally
in 2013.
$162
$115
In MA the
reduction was
7.3% or
$182 million.
$98
MA
TX
WA
2012
$3,475
$2,471
$2,042
$1,598
$1,460
$1,077
$1,061
$918
$798
$23,813
NY
$97
NC
$86
CA
$70
MD
$54
$54
Ill
PA
2013
$3,216
$2,289
$1,897
$889
$1,354
$937
$922
$776
$697
$20,912
Source: NIH, Research Portfolio Online Reporting, U.S. Census Bureau
Job Listings on MassBio.org
In June and July of
2014, average daily
listings on
MassBio.org have
been consistently
above 1,400 jobs.
MassBio.org is not
a comprehensive
listing of all jobs
available in the
industry in
Massachusetts.
Given its significant
volume, it does
provide a
statistically strong
sampling in
determining job
hiring trends.
Average Daily # of Job Listings for the Month of May, 2009-2014
1,394
1,320
1,005
1,005
980
786
504
2008
2009
2010
2011
2012
2013
2014
Top NIH Funded Independent Hospitals 2013
The Top 5
NIH-funded
independent
research
hospitals are in
Boston.
Please note:
NIH lists hospitals that
are part of universities
separately.
Hospital
MASSACHUSETTS GENERAL HOSP
BRIGHAM AND WOMEN'S HOSPITAL
CHILDREN'S HOSPITAL CORPORATION
City
BOSTON
BOSTON
BOSTON
BETH ISRAEL DEACONESS MEDICAL CENTER
DANA-FARBER CANCER INST
CHILDREN'S HOSP OF PHILADELPHIA
CINCINNATI CHILDRENS HOSP MED CTR
BOSTON
BOSTON
PHILADELPHIA
CINCINNATI
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
Awards
Funding
783 $323,961,795
576 $315,919,592
303 $126,812,298
267
201
206
257
$118,785,811
$115,844,948
$108,503,611
$105,269,995
MEMPHIS
99
$64,634,574
NEW YORK STATE PSYCHIATRIC INSTITUTE
BOSTON MEDICAL CENTER
NEW YORK
BOSTON
98
83
$45,962,566
$34,357,978
ROSWELL PARK CANCER INSTITUTE CORP
TUFTS MEDICAL CENTER
BUFFALO
BOSTON
63
64
$34,281,239
$30,823,441
Source: NIH, Research Portfolio Online Reporting
Top Massachusetts NIH Funded Non-Profits, 2013
Massachusetts
non-profits are
significant
recipients of NIH
funding.
Johns Hopkins
University and
its Medical
School is tops
nationally, with
$575 million in
total NIH
awards.
Institution
HARVARD UNIVERSITY (MEDICAL SCHOOL)
UNIV OF MASSACHUSETTS MED SCH WORCESTER
HARVARD UNIVERSITY (SCH OF PUBLIC HLTH)
BOSTON UNIVERSITY MEDICAL CAMPUS
BROAD INSTITUTE, INC.
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
HARVARD UNIVERSITY
TUFTS UNIVERSITY - Boston
BOSTON UNIVERSITY
JOSLIN DIABETES CENTER
NEW ENGLAND RESEARCH INSTITUTES, INC.
BRANDEIS UNIVERSITY
NORTHEASTERN UNIVERSITY
MASSACHUSETTS EYE AND EAR INFIRMARY
IMMUNE DISEASE INSTITUTE, INC.
WHITEHEAD INSTITUTE FOR BIOMEDICAL RES
UNIVERSITY OF MASSACHUSETTS AMHERST
FORSYTH INSTITUTE
TUFTS UNIVERSITY MEDFORD
SCHEPENS EYE RESEARCH INSTITUTE
Funding
Grants
$185,223,961
388
$130,350,480
312
$115,870,367
188
$107,762,256
240
$98,855,705
57
$94,736,982
234
$51,828,312
124
$48,040,076
136
$45,230,769
122
$37,642,908
40
$29,154,452
11
$25,846,230
85
$22,360,166
53
$19,828,336
35
$13,767,584
23
$11,193,456
26
$10,939,571
37
$8,752,534
20
$8,602,192
33
$6,564,383
15
Source: NIH, Research Portfolio Online Reporting
Venture
investment in MA
was rose to $941
million in
2013.
Venture Capital Investment
Investment in Massachusetts Biotech Companies, 2002-2013
Massachusetts
received over
20% of all VC
investment in
biotechnology in
the U.S.
Source: PWC MoneyTree Historical data and Evaluate Pharma.
Top 15 VC Financings in MA - 2013
Company
$ (million)
Series
Moderna Therapeutics
110.0
Series B
Karyopharm Therapeutics
67.2
Series A, B
Dicerna Pharmaceuticals
60.0
Series C
Jounce Therapeutics
47.0
Series A
Zafgen
45.0
Series E
Radius Health
43.0
Series D
Avedro
43.0
Series D
Aileron Therapeutics
42.0
Series D, E
Akebia Therapeutics
41.0
Series C
Civitas Therapeutics
38.0
Series B
Tokai Pharmaceuticals
35.5
Series E
Syros Pharmaceuticals
30.0
Series A
Syndax Pharmaceuticals
26.6
Series B
Blueprint medicines
25.0
Series B
Ocular Therapeutix
23.8
Series D
Source: Evaluate Pharma ®
Biotech VC in Massachusetts by Location
$500+ million
dollars in VC
went to
Cambridge-based
biotechs in 2013.
Companies in
other
Massachusetts
communities
garnered almost
$400 million.
Source: EvaluatePharma®
Seed Stage Funding
Seed stage
At this initial stage, the company has a concept or
product under development, but is probably not fully
operational and has usually in existence less than 18
months.
Source: PWC MoneyTree Historical data .
Massachusetts Seed Stage 5-year trends
MA seed stage
deals have
grown in
number and in
size since
1999.
In the most
recent 5 years,
MA companies
have received
33.4% of all
seed funding
for biotech in
the U.S.
Value
1999-2003 $52,054,900
2004-2008 $436,981,800
2009-2013 $761,912,400
Deals
20
76
95
MA share of U.S. Seed stage
funding for biotech . . .
33.4%
Average Seed Deal Size
23.7%
$8,020,131
2009-2013
13.1%
2004-2008
1999-2003
$5,749,761
$2,602,745
1999-2003
2004-2008
2009-2013
Source: PWC MoneyTree Historical data .
5-year Trends in Seed Stage Financing
Seed Stage as percentage of overall VC deals . . .
15.8%
Over the past
decade, MA
has
outperformed
the nation in
percentage of
deals and
investment at
the seed
stage.
10.2%
10.7%
US
MA
7.6%
2.4%
2.0%
1999-2003
2004-2008
2009-2013
Seed Stage share of overall biotech VC investment . . .
19.8%
21.1%
18.5%
18.6%
US
MA
11.7%
8.1%
Source: PWC MoneyTree Historical data .
1999-2003
2004-2008
2009-2013
MA Seed Stage Funding by quarter, 1999-2013
$120,000,000
but, there has
been a drop
since the 20082010 high
watermarks.
$100,000,000
$80,000,000
$60,000,000
$40,000,000
The “Good Old Days” weren’t
so good . . .
$20,000,000
$0
Source: PWC MoneyTree Historical data .
MA Seed Stage Funding - Annual, 1999-2013
2014 will be a
revealing year
for seed
funding. Will
MA move above
the 5-year
trending in
funding?
$300,000,000
$250,000,000
$200,000,000
$198,917,200 in
Seed funding in
MA is needed
for the 5-year
period ending in
2014 to equal
that of the prior
5-year period.
5-yr average, $152,382,480
$150,000,000
$100,000,000
15-yr average, $83,429,940
$50,000,000
$0
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Source: PWC MoneyTree Historical data .
2013: The IPO Comeback
An initial public
offering, or IPO,
is the first sale
of stock by a
company to the
public. If the
company has
never issued
equity to the
public, it's
known as an
IPO.
There were
virtually no IPOs
in 2008 or 2009,
with a modest
comeback
beginning in
2010.
Acceleron
$93 million*
Agios Pharmaceuticals $122 m
Bind Therapeutics
$70.5 m
Bluebird Bio $116 m
Enanta Pharmaceuticals
$65 m
Epizyme $80 m
Foundation Medicine $106 m
Karyopharm $109 m
Tetraphase Pharmaceuticals
$80 m
*figures refer to “offer amounts” (investment secured) at time of IPO.
Source: Nasdaq.com, BioSpace
2014: IPOs Continued
Fourteen IPOs
through July of
2014, sets an
annual record
in IPOs for
Massachusetts
biotech
companies.
$90 million*
$66 m
$91 m
$59.5 m
$12 m
$52 m
$90 m
$96 m
$84 m
$32.7 m
$65 m
$100 m
$90 m
$65 m
*figures refer to “offer amounts” (investment secured) at time of IPO.
Source: Nasdaq.com, BioSpace
Industry IPOs by Geography, since 2013*
Massachusetts
Pennsylvania
6 IPOs
$399 million aggregate raised
$66.5 million average initial offering
California
37 IPOs
$2.57 billion aggregate raised
$69.4 million average initial offering
24 IPOs
$1.9 billion aggregate raised
$79.2 million average initial offering
New York
5 IPOs
$402 million aggregate raised
$80.3 million average initial offering
New Jersey
9 IPOs
$520 million aggregate raised
$57.8 million average initial offering
*through July 25, 2014. Includes leading four states only.
Source: Nasdaq.com, BioSpace
Drug Development Pipeline, by Phase
535
1,384 drug candidates in development
6% of the global pipeline
12% of the U.S. pipeline
452
164
160
64
9
Research Project
Pre-Clinical
Phase I
Phase II
Phase III
Filed
Source: EvaluatePharma®, July 2014
Behind the Numbers
535
Research Project
Phase
At this “discovery
stage” the goal is to
find a new molecule
or chemical that can
be a useful drug
through extensive
laboratory work in
which drug targets
are defined, screened
and the formulation
and delivery
mechanism of the
drug candidate is
developed.
452
ALSTDI is a Cambridge nonprofit that seeks to end ALS
“Lou Gerhrig’s Disease”, a
progressive neurodegenerative
disease that causes muscle
weakness, paralysis, and
ultimately, respiratory failure.
164
160
64
9
Projects TDI 174/175
Pathology associated with proteins that normally assist in RNA processing and mutations in
the genes that encode them have been associated with ALS. These two projects are aimed at
developing therapeutics that will influence RNA binding and metabolism and may stabilize
susceptible neurons.
Source: Evaluate Pharma ®, ALSTDI website.
Behind the Numbers
Phase II
535
452
Phase II clinical
trials subject
typically include
100-300 patients to
assess the efficacy
and safety of a
drug. A drug is not
presumed to have
therapeutic value at
this stage. Phase
III trials, with 1000
or more patients,
determines
therapeutic effect.
Synta is a Lexington-based
company focused on discovering,
developing and commercializing
small molecule drugs to extend
and enhance the lives of patients
with severe medical conditions,
including cancer and chronic
inflammatory diseases.
164
160
64
9
Elesclomol
Elesclomol is in a Phase 2 clinical study in patients with recurrent ovarian cancer, fallopian tube
cancer, or primary peritoneal cancer who have progressed while receiving platinum-based therapy.
Source: Evaluate Pharma ®,Synta Pharmaceuticals website.
Massachusetts Pipeline by Therapeutic Area
Gastro-Urinary, 2%
Respiratory, 2%
Dermatology, 1%
Blood, 3%
Endorine, 3%
Cardiovascular, 3%
Gastro-Intestinal, 4%
Oncology
35%
Therapeutic Area
Candidates
Oncology
487
Systemic Anti-infectives
222
Central Nervous System
196
Other
102
Sensory
62
Musculoskeletal
75
Gastro-Intestinal
51
Cardiovascular
48
Endorine
42
Blood
34
Gastro-Urinary
24
Respiratory
27
Dermatology
14
Total
1384
Musculoskeletal
5%
Sensory
5%
Other
7%
Central Nervous
System
14%
Systemic Antiinfectives
16%
Source: EvaluatePharma®, May, 2014
Recent Drug Approvals
for Massachusetts Companies
2013:
Kynamro (Genzyme) to treat rare forms of high cholestorol
Tecfidera (Biogen Idec) best-in-class treatment for relapsing multiple
sclerosis
Aptiom (Sunovion) treats seizures associated with epilepsy
2014:
Alproliz (Biogen Idec) for the treatment of hemophilia B
Entyvio (Millennium, The Takeda Oncology Company) for treatment of
adults with ulcerative colitis and Chrohn’s Disease.
Sirextro (Cubist) for treatment of acute bacterial skin and skin structure
infections
Source: CenterWatch
Changing the Lives of Patients
Over 160 drugs
have been
commercialized
by current
Massachusettsheadquartered
companies.
Sources: Developed from multiple sources including EvaluatePharma®, emedicine medscape, NCBI, CDC.
Largest Industry Employers in MA, 2013
1
2
4
5
6
7
8
9
10
11
12
13
14
Genzyme, a Sanofi Company
Biogen Idec
Parexel International
Pfizer
Novartis
Hologic
Shire
Vertex
Thermo Fisher Scientific
EMD Millipore
Millennium: Takeda Oncology
Charles River Laboratories
AstraZeneca
EMD Serono
Nova Biomedical
4,356
2,800
2,800
2,700
2,100
1,800
1,500
1,450
1,400
1,261
1,204
960
900
855
855
15
16
18
19
20
21
22
23
24
25
26
PerkinElmer
850
AbbVie
700
Sunovion Pharmaceuticals (DSP) 650
Cubist
638
Merck
500
Bristol-Myers Squibb
400
Lantheus
375
Alkermes
325
New England Biolabs
280
Organogenesis
274
Cell Signaling
270
Immunogen
270
28 Ironwood
260
29 Sanofi
250
Amgen
250
Sources: MassBio Membership Reports & Surveys; Boston Business Journal Book of Lists, 2013
Life Sciences Lab Inventory Growth
2014 Construction
Completed in 2013
21,203,999 s.f.
16,063,990 s.f.
Vertex, Boston
Novartis, Cambridge
Pfizer, Cambridge
2007
Lonqwood Center, Boston
2014
Biogen Idec, Cambridge
Alexandria Center, Cambridge
Source: Colliers Meredith & Grew, Life Science Review, 2007-2013, CBRE- NE BioView, 2014.
Industry Geography
Top 10
Communities
by number of
BiopPharma
Companies*
Cambridge (130)
Boston (41)
Worcester (31)
Waltham (26)
Lexington (25)
Woburn (24)
Watertown (16)
Bedford (14)
Marlborough (9)
Billerica (9)
*The Bureau of Labor
Statistics indicates 738
biotechnology and
pharmaceutical
establishments in MA.
For this list, MassBio used
its own database and the
MassBio/MHT 2014
Complete Guide, which
include 431 company
addresses.
What’s in a Number?
Please note: Prior to 2012, MassBio used two different federal sources for
employment data. In order to present more consistent employment data on a more
timely basis, we no longer use County Business Patterns (CBP) data of the U.S.
Census Bureau but rely primarily on the U.S. Bureau of Labor Statistics, Quarterly
Census of Employment and Wages (QCEW) for this data.
As a result, historical employment data found in the 2012 -2014 Snapshots vary from
that found in past reports. Though the historical annual employment figures vary by
about 5% between the 2012 Snapshot and those of past years, the trend lines are
very similar.
Why use the QCEW? QCEW data is comprised of employment and wages from
unemployment insurance (UI) tax reports submitted by employers and is augmented
by both BLS worksite reports and the Annual Re-filing Survey (ARS), which surveys
one quarter of all private-sector establishments each year. The QCEW data is
available on a more timely basis than the CBP and is directly related to the state’s ES202 data, providing an additional, ongoing corroborative source.
What’s in a Number?
What is considered “biopharma” employment?
Using the North American Industry Classification System (NAICS), with which QCEW data is reported,
MassBio has determined that several NAICS classifications can be considered part of the biotechnology
and pharmaceutical industry. However, only in certain cases can the industry claim 100% of any one
NAICS code. MassBio determined that a percentage of some industry classifications could be used in
estimating overall industry employment. In some cases, the percentage determination for certain industry
codes was based on reports developed by other organizations. The following NAICS codes are utilized:
NAICS 3254: Pharmaceutical MFG, including biologics (100%)
NAICS 541711: Research and Development in Biotechnology (100%)
NAICS 541712: R&D in Physical, Engineering, and Life Sciences (except biotech) (22%)
NAICS 334516: Analytical Laboratory Instrument MFG (30%)
NAICS 54138: Testing Laboratories (9%)
NAICS 622: Hospitals (4.5%)
NAICS 61131: Universities (1.9%)
NAICS 621551: Medical testing laboratories (100%)
NAICS 4242, Drug merchant wholesalers, is no longer included in any current or annual employment
figures. NAICS 621511, Medical Laboratories, is included. Prior to 2013, we omitted Medical Laboratories,
as these laboratories are health care services related, providing services to the medical delivery and
patient care system, rather than the biopharma research development and manufacturing industry. We now
acknowledge that Medical Laboratories are closely connected to the biopharma industry, requiring similar
capacity and skills found in the biopharma industry. MassBio also tracks employment for “green
biotechnology” classifications: 325199. 325221, 311222, and 311223. However, the QCEW does not reveal
employment data for these categories beyond minimum ranges, so this data is not included in the
employment figures presented in this Snapshot nor is it factored in comparisons with other states.
Questions?
As the premier source of information on biotechnology in
Massachusetts, MassBio tracks industry statistics over time
and issues an overview Industry Snapshot each year.
For more information, contact:
Peter Abair, Director of Economic Development
& Global Affairs
617-674-5130
[email protected]